WHO ICTRP trial
PLATO - Personalising anal cancer radiotherapy dose
ISRCTN88455282 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN88455282 |
|---|---|
| Public title | PLATO - Personalising anal cancer radiotherapy dose |
| Scientific title | PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5 |
| Primary sponsor | University of Leeds |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Ireland;United Kingdom;England;Northern Ireland;Scotland;Wales |
| Conditions | Anal cancer Cancer Malignant neoplasm of anus and anal canal |
| Interventions | Current interventions as of 03/04/2023: ACT3 (recruitment end date: 31/10/2023): Observation arm No further treatment after local excision. Intervention arm Either a 3D conformal plan or a single phase inverse-planned IMRT treatment plan… |
| Registration date | Mar 8, 2016 |
| Target size | 711 |
| Secondary IDs | CPMS 31184, IRAS 204585 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: